12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Leukine sargramostim: Phase II data

The open-label, U.S. Phase II E1608 trial in 245 patients showed that subcutaneous Leukine sargramostim plus IV Yervoy ipilimumab led to a 1-year OS of 68.9% vs. 52.9% for IV Yervoy alone. Tumor shrinkage rates were comparable between arms (11-14%). The combination...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >